Mayzent, Zeposia May Lose Ground in Canada, Report Finds

From: Multiple Sclerosis News Today

By: Marta Figueiredo, PhD

 

Mayzent (siponimod) and Zeposia (ozanimod), the two sphingosine-1-phosphate (S1P) receptor modulators most recently approved in Canada for treating multiple sclerosis (MS), showed strong launches in the country, according to the latest Spherix Global Insights’ report…(read more).